Stability-indicating RP-HPLC method development and validation for simultaneous estimation of bisoprolol fumarate and amlodipine besylate in bulk and in tablet dosage form

Rameshwar Bhausaheb Gholve*, Sanjay Sudhakar Pekamwar, Tukaram Mohanrao Kalyankar
Department of Pharmaceutical Chemistry, School of Pharmacy, Swami Ramanand Teerth Marathwada University, Nanded, India.

ARTICLE INFO
Received on: 04/06/2021
Accepted on: 21/07/2021
Available Online: 05/12/2021

Key words: RP-HPLC, bisoprolol, amlodipine, forced degradation, solution stability, validation.

ABSTRACT
A novel chromatographic method has been developed with a stability-indicating feature for simultaneous estimation of bisoprolol fumarate (BSL) and amlodipine besylate (AMD) in bulk and in tablet dosage form with minimized drug extraction steps. The chromatographic analysis was executed by the isocratic elution mode using Oyster ODS3 (150 × 4.6 mm, 5 µm) column (Merck & Co.) as the stationary phase at ambient temperature (about 25°C) with 1.0 ml/minute flow rate and 20 mM phosphate buffer with pH 2.5 (adjusted by 5% orthophosphoric acid):methanol:acetonitrile (42:29:29, v/v/v) as eluents at a wavelength of 230 nm. The retention time was found to be 2.543 and 4.883 minutes for bisoprolol and amlodipine, respectively. The method was found to be linear in the concentration range of 60.08–140.19 µg/ml for BSL and 59.73–139.37 µg/ml for amlodipine with squared correlation coefficient (R²) of 0.999 in both cases. Individual drug substances and their combination drug product were exposed to conditions like acid, alkali, oxidative, thermal, photolytic, and humidity degradation; the degradation peaks were well separated from active analyte peaks. The acid-, alkali-, thermal-, and photolytic-induced stress studies signified the formation of a variety of degradants. Hence, it is recommended that BSL and AMD drug substances, as well as drug products, should be stored in tightly closed container protected from light and heat. The method was validated for specificity, linearity, quantitation limit, detection limit, accuracy, precision, robustness, and solution stability as per International Conference on Harmonization (ICH) guidelines and effectively used for regular analysis.

INTRODUCTION
Bisoprolol fumarate (BSL) is chemically known as (2RS)-1-[(4-[(2-(1-methylethoxy)ethoxy)methyl]phenoxy)-[(1-methylethyl)amino]propan-2-ol fumarate (Fig. 1a), which is a white or almost white powder and is official in the United State Pharmacopeia, European Pharmacopoeia, and Indian Pharmacopoeia. It is categorized as a β-adrenoceptor antagonist (European Pharmacopoeia 10.0, 2020; Indian Pharmacopoeia, 2018; United State Pharmacopeia, 2020).

Amlodipine besylate (AMD) is chemically known as 3-ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulfonate (Fig. 1b), which is white or almost white powder and is official in the United State Pharmacopeia, European Pharmacopoeia, and Indian Pharmacopoeia. It is a calcium channel blocker categorized as antihypertensive and antianginal agents (European Pharmacopoeia 10.0, 2020; Indian Pharmacopoeia, 2018; United State Pharmacopoeia, 2020).

Individually or in combination, BSL and AMD are widely used as antihypertensive drugs and both the drugs have different and complementary mechanisms of actions to decrease blood pressure. The combination therapy of BSL and AMD shows an additive effect in blood pressure control, resulting in reduced risk of cardiovascular events. Hence, the fixed dose combination of BSL and AMD is more effective and significantly better than...
monotherapy as the side effects decrease and the compliance of patient increases (Hostalek and Koch, 2016).

To know the inherent stability characteristics of active component(s), stress testing needs to be carried out (ICH, 2003). Related substances and/or impurities are generated during the manufacturing process and/or degradation products from inappropriate storage or handling of material or as metabolites which can be active, inactive, or even toxic, and significantly affects the results with respect to quality, safety, and efficacy. Good stability-indicating methods having the capability to resolve degradation products or impurities significantly from the active components (Alsante et al., 2011; Aubry et al., 2009; Blessy et al., 2014; Thakur et al., 2015).

Nowadays, several analytical reports employ the validated reverse phase high-performance liquid chromatography due to the advantage of it being efficient, easy to use, and accurate, as well as its ability to provide the best separation of analytes. Also, high performance liquid chromatography (HPLC) equipped with different types of detectors, like Ultra-Violet (UV)/ Photo-Diode Array (PDA)/ Fluorescence/ Refractive Index (RI)/ Evaporative Light Scattering Detector (ELSD)/ Mass (MS)/ Pulsed Electrochemical Detector (PED)/ Pulsed Amperometric Detector (PAD), have additional advantages in the field of drugs analysis. The HPLC technique is widely used for the determination of drugs in bulk and in pharmaceutical dosage forms, as well as in biological fluids. It is also applicable for developing a stability-indicating method which helps in the selection of appropriate storage conditions (Da Silva Medeiros et al., 2020; Gamal, 2020; Hosny, 2020; Mohammed et al., 2021).

Surveys of the literature show that few methods are reported for the simultaneous estimation of BSL and AMD by HPLC techniques. The available methods have some limitations such as time-consuming procedures, low resolution, and long run time; forced degradation study was carried out on drug substance and on drug product; not for photolytic and humidity stress conditions (Patil et al., 2017); forced degradation study was not carried out (Baokar et al., 2011; Pant and Pal, 2012; Patil et al., 2014), but forced degradation study was carried out only on drug product and not on drug substance and humidity stress condition (Vora and Kadav, 2008). In addition to this, some robustness parameters along with mobile phase preparation, for standard and sample solution stability, need to be analyzed. Therefore, an attempt has been made to execute stress study on both drug substances individually and their combination drug product to develop a validated reverse phase - high performance liquid chromatography (RP-HPLC) method having the stability-indicating feature for the simultaneous estimation of BSL and AMD which is more simple, rapid, sensitive, specific, precise, accurate, and robust.

**MATERIALS AND METHODS**

**Chemicals/materials**

BSL (Batch no.: 2010005540, Purity: 99.74%) and AMD (Batch no.: 2010005135, Purity: 99.96%) pure drug samples were gifted by Unichem Laboratories Ltd., Goa, India. All the chemicals like potassium dihydrogen phosphate (PDP) (Batch no.: H14A/1514/1306/53, Make: SD Fine Chem Ltd., Mumbai, India), acetonitrile (Batch no.: 1092840616, Fischer Scientific India Pvt. Ltd., Mumbai, India), orthophosphoric acid (Batch no.: 2467211117, Make: Research Lab Fine Chem Industries, Mumbai, India), 6% v/v hydrogen peroxide (Batch no.: MCM-1171, Make: Molychem, Mumbai, India), sodium hydroxide (Batch no.: DH6D662478, Make: Merck, Mumbai, India), hydrochloric acid (Batch no.: CK66660816, Make: Merck, Mumbai, India), and water were of HPLC grade or equivalent grade were used during the experiments. BSL and amlodipine tablets were 5/5 mg (CORBIS® AM – 5)—each film-coated tablet containing BSL 5

![Figure 1. Structure of (a) BSL and (b) AMD.](image)

![Figure 2. Chromatograms of (a) blank, (b) standard, and (c) sample.](image)
mg and AMD equivalent to amlodipine 5 mg was procured from a local medical store (Batch no.: 2013406TT, Marketed by: Torrent Pharmaceuticals Ltd., Mehsana, India, Make: Ordain Health Care Global Pvt. Ltd., Kanchipuram, India).

Instruments

Weighing of the materials was carried out using an analytical weighing balance (Make: Citizon, Model: CY204). A digital ultrasonic cleaner (Make: Labman Scientific Instruments, Model: LMUC-3) was utilized for the sonication. A digital pH meter (Make: Labtronic Laboratory Instruments, Model: LT49) was employed for the estimation of solution pH. The hot air oven (Make: Bio-Technics India, Model: BTI-29), stability chamber (Make: Labline Stock Centre, Model: GMP), and photostability chamber (Make: S R Lab Instruments India Pvt. Ltd., Model: SRL-PHSC-11-A) were used during the forced degradation study. A refrigerator (Make: LG, Model: GL-A282SPZL) was used during the solution stability study. A water purification system (Make: Analytical Technologies Limited, Model: WPS211) used to collect ultrapure water for the experiment. The method was developed on an Oyster ODS3 (150 × 4.6 mm, 5 µm) column (P/N: S670153, Make: Merck & Co.) connected to a HPLC system (Make: Shimadzu, Model: SCL-10Avp) equipped with a UV detector having rheodyne sample injection port with a 20 µl loop. The chromatographic system was controlled by LC solution version 1.25, which was used for the data collection as well as data processing.

Chromatographic conditions

The chromatographic conditions for analysis utilized during the experimental work are given in Table 1.

Preparation of 20 mM phosphate buffer of pH 2.5

PDP (2.72 g) was weighed and transferred into 1,000 ml water, sonicated for 10 minutes, and dissolved. pH 2.5 was adjusted with 5% orthophosphoric acid solution and filtered by using 0.45 µm nylon membrane filter (Cat no.: HNNX0902XXXX104, Make: Advanced Microdevices Pvt. Ltd.) under vacuum filtration.

Preparation of the mobile phase

290 ml of methanol and 290 ml of acetonitrile were mixed with 420 ml of 20 mM phosphate buffer having a pH 2.5 and degassed by 10 minutes of sonication.

Preparation of the standard solution

BSL (10 mg) and AMD (13.9 mg; equivalent to 10 mg of amlodipine) standards were weighted and transferred into a 100 ml dry volumetric flask. 70 ml of the diluent was added and sonicated with intermediate shaking for 10 minutes to dissolve. After that, it was allowed to reach room temperature and with a diluent it was filled up to the mark and mixed well (concentration of BSL = 100 µg/ml; concentration of amlodipine = 100 µg/ml). To confirm the suitability of standard, it was prepared in duplicate.

Preparation of the sample solution

The average weight of BSL and amlodipine tablets 5/5 mg (CORBIS® AM – 5) was determined from the weight of 20 tablets, and these tablets were powdered with the help of mortar and pestle. Subsequently, 373.6 mg (equivalent to 10 mg BSL and 10 mg amlodipine) of this fine powder was transferred into a 100 ml dry volumetric flask. 70 ml of the diluent was added and sonicated for 25 minutes with intermediate shaking. After sonication, it was allowed to reach room temperature and with a diluent it was filled up to the mark and mixed well. Finally, the resulting sample solution was filtered using Whatman filter paper (Cat No.: 1001-125, Make: GE Healthcare UK Ltd.) by discarding initial 5 ml of the filtrate and used as assay sample solution.
The proposed RP-HPLC method was validated as per the ICH guideline Q2 (R1) (ICH, 2005).

Specificity

For specificity, blank solution interference at the retention time of BSL and AMD peaks was checked. Also, specificity was studied in forced degradation studies with a twofold increase in the actual run time of isocratic mode of elution to ensure that no late eluting degradation peaks. In this study, forced degradation was carried out by subjecting each drug substance individually and drug product sample (CORBIS® AM – 5) with known concentration to various stress conditions like acid (5 N HCl, 3 hours at room temperature), alkali (5 N NaOH, 3 hours at room temperature), oxidative (6% v/v, H₂O₂, 3 hours at room temperature), thermal (dry heat at 60°C for 48 hours in hot air oven), photolytic (UV light for 24 hours in photostability chamber), and humidity (75% relative humidity for 48 hours in stability chamber) degradations. Similarly, blank solutions (without active components) were prepared for acid, alkali, and oxidative stress conditions to check any interference at retention time of active analyte peaks. However, stress degradation samples were analyzed by using the proposed RP-HPLC method and results for mass balance (% assay + % degradation) were determined for all the stressed samples against the standard and compared with the unstressed sample.

System suitability and system repeatability

The system suitability parameters such as retention time, tailing factor, theoretical plate count, and resolution were reported from the first injection of standard solution. The systems repeatability parameters are determined by injecting first standard solution (5 replicates) and second standard solution (1 replicate) in the chromatographic system and afterward determining the % relative standard deviation (% RSD) for first standard and % relative difference for second standard.

Linearity

Linearity was established at five different concentration levels prepared from standard stock solution (concentration of BSL = 500.69 µg/ml and amlodipine = 497.76 µg/ml). It was carried out from 60% to 140% of the nominal working concentration in the range of 60.08–140.19 µg/ml and 59.73–139.37 µg/ml for BSL and AMD, respectively. The linearity graph for concentration versus peak area response was plotted and determined the squared correlation coefficient ($R^2$).

Detection limit (DL) and quantitation limit (QL)

The DL and QL of BSL and AMD were determined based on the standard deviation of response (residual value) and the slope method. As per the ICH guidelines, the BSL and AMD calibration curves were determined by using the following formulae:

\[
DL = 3.3 \times \frac{\sigma}{S} \quad \text{and} \quad QL = 10 \times \frac{\sigma}{S}
\]

where $\sigma$ = the standard deviation of the response and $S$ = the slope of the calibration curve.

Accuracy

Accuracy were assessed by analyses in triplicate sample containing placebo mixture with BSL and AMD at three concentrations: 60%, 100%, and 140% of the nominal working concentration. At each level, samples were prepared in triplicate and every sample was injected once, and the mean recovery for triplicate samples at every concentration level was determined.

Precision

For the assay determination of BSL and AMD, the precision study was executed by using homogeneous sample.

Figure 4. Chromatogram of alkali-stressed (a) blank, (b) BSL, (c) AMD, and (d) sample.
Method repeatability

Method repeatability of BSL and amlodipine tablets 5/5 mg (CORBIS® AM – 5) using batch no. 2013406TT (Marketed by: Torrent Pharmaceuticals Ltd., Mehsana, India) was established by injecting six sample preparations for assay as per proposed method. The % assay, % RSD, and 95% confidence interval (95% CI) were calculated. Also, the system suitability and the system repeatability results were determined.

Intermediate precision

Intermediate precision was demonstrated from six determinations of the same sample of BSL and amlodipine tablets 5/5 mg (i.e., batch, storage conditions, container, etc.) tested for method repeatability by different analysts on different days. Six replicate samples for the assay were prepared and the % assay, % RSD, and 95% confidence interval (95% CI) were calculated. The average results obtained in method repeatability were compared with the intermediate precision study. Also, the system suitability and the system repeatability results were determined.

Robustness

The method robustness was established by carrying out the deliberate alteration in method parameters. Filter compatibility was established for BSL and amlodipine tablets 5/5 mg (CORBIS® AM – 5) using three sample preparations and each sample was divided into three parts. First part was filtered by using Whatman filter (Cat no. 1001-125, Make: GE Healthcare UK Ltd.) by discarding the initial 5 ml of the filtrate (as per method). The second part was filtered by using 0.45 µm Polyvinylidene Fluoride (PVDF) syringe filter (Cat no. SYVF0602MNXX104, Make: Advanced Microdevices Pvt. Ltd.) by discarding the initial 5 ml of the filtrate, and third part was filtered by using 0.45 µm nylon syringe filter (Cat no. SYNN0602MNXX104, Make: Advanced Microdevices Pvt. Ltd.) by discarding the initial 5 ml of the filtrate and used as the sample solution. The % assay and % relative difference were calculated.

The extraction efficiency of method was demonstrated by carrying out alteration into sonication time during sample preparation from 20 to 30 minutes. Alteration in sonication time for preparation of sample was tested with three replicate preparations of sample of BSL and amlodipine tablets 5/5 mg (CORBIS® AM – 5) for each altered condition for calculating the % assay and % relative difference.

As part of the robustness study, deliberate change in chromatographic parameters with respect to changes in flow rate (±0.1) from 0.9 to 1.1 ml/minute, change in the buffer composition of mobile phase (±10%) from 378:290:290 v/v to 462:290:290 v/v, change in pH (±0.2) of mobile phase buffer from pH 2.3 to 2.7, change in the quantity of PDP for mobile phase buffer (±10%) from 2.448 g/1,000 ml to 2.992 g/1,000 ml, and every changed condition impact on the method was evaluated. The results of system suitability and system repeatability parameters were checked for each changed conditions.

Solution stability

The standard solution stability was evaluated on duplicate preparations stored at room temperature and in the refrigerator (2°C–8°C), and assessed after day 1 and day 2. The results of the stored standard solution with freshly prepared standard solution were compared and the % relative difference was calculated.

The sample solution stability was evaluated on three sample preparations (as per method) stored at room temperature and in the refrigerator (2°C–8°C), and assessed after day 1 and day 2. The results of the stored sample solution with initial sample solutions were compared and the % relative difference between the percent assays was calculated.

Mobile phase preparation stability was assessed at bench top (room temperature) after day 1 and day 2. During evaluation of the mobile phase’s stability, the results for change in appearance, system suitability, and system repeatability were checked.

Range

Linearity as well as accuracy for BSL and AMD was checked from 60% to 140% of the nominal working concentration. The method range was checked based on suitable linearity, accuracy, and precision results.

RESULT AND DISCUSSION

Method development and chromatographic conditions optimization

The consideration of specificity, accuracy, precision, linearity, robustness, and solution stability parameters for
development and validation of stability indicating method for BSL and AMD in bulk and in tablet dosage form. After optimization of a number of changed compositions, mobile phase was selected and afterward detection wavelength and flow rate were optimized. Also, method optimization performed by using the columns like Oyster ODS3 (150 × 4.6 mm, 5 µm) column (P/N: S670153, Make: Merck) and ODS Hypersil, 250 × 4.0 mm, 5 µm (P/N: 30105-254030, Make: Thermo Scientific). The organic modifiers like methanol and acetonitrile were used along with 20 mM phosphate buffer at various pH levels, such as 2.3, 2.5, and 2.8, to obtain the best peak shape with optimal resolution.

Finally, the mobile phase comprised the ratio of 420:290:290 v/v/v of 20 mM phosphate buffer pH 2.5 ± 0.05 (adjusted with 5% orthophosphoric acid):methanol:acetonitrile was selected for simultaneous estimation of BSL and AMD because it retained both the peak efficiently in short time with satisfactory plate count (number of theoretical plates), tailing factor (symmetry factor), and resolution. Assay was performed by 1.0 ml/minute flow rate at ambient (about 25°C) column temperature and recorded the response with UV detector at 230 nm. All quantitative calculations for assay of BSL and AMD were made on the basis of peak area response.

**METHOD VALIDATION**

**Specificity**

Specificity was established by demonstrating that there is no blank interference with BSL and AMD peaks (Fig. 2). The forced degradation study was executed and interference was not observed from the degradation peaks at the retention time of BSL and AMD. The results of mass balance (% assay + % degradation) was determined for each stressed sample against standard and compared with unstressed sample. Mass balance data for BSL and AMD in their individual drug substance solution clearly showed that the response of BSL decreased in the acid-stressed sample, while the response of AMD decreased in acid- and alkali-stressed sample along with increase in the response of degradation peaks. In the acid-stressed sample, the major degradant observed at 2.263 minute and 3.221 for BSL and AMD respectively. The major degradant for AMD was observed at 3.570 minute in alkali-stressed and at 3.128 minute in photolytic-stressed sample. Hence, the forced degradation studies showed that BSL drug substance was stable to alkali, oxidative, thermal, photolytic and humidity stressed condition while susceptible to acid-stressed condition; while AMD drug substance was stable to oxidative, thermal and humidity stressed condition while susceptible to acid, alkali and photolytic stress conditions. Mass balance data for BSL and AMD in the sample solution clearly shows that the response of BSL decreased in the acid-stressed samples while response of AMD decreased in acid, alkali, thermal and photolytic-stressed samples along with increase in
the response of degradation peaks. In the acid-stressed sample, the major degradant observed at 2.267 and 5.482 minute for BSL and AMD, respectively. In alkali-, thermal-, and photolytic-stressed sample, the major degradant for AMD were observed at 3.574, 5.390, and 3.111 minutes, respectively. Hence, the forced degradation studies performed on drug product sample demonstrate that, BSL was stable to alkali-, oxidative-, thermal-, photolytic- and humidity-stressed condition and susceptible to acid-stressed condition; AMD was stable to oxidative and humidity stressed condition and susceptible to acid, alkali, thermal and photolytic-stressed condition.

A forced degradation study result shows that both drugs are stable at the oxidative and humidity stress condition. BSL is more stable in alkali and photolytic stress conditions and unstable in acid medium, while AMD is unstable in acid, alkali, thermal, and photolytic stress conditions. Hence, it is recommended that the BSL and AMD drug substances as well as the drug product should be stored in tightly closed containers and protected from light and heat. The forced degradation study results are summarized in Table 2. The chromatograms of stressed samples (Fig. 3–6) show that the peaks due to degradation were well resolved from the drugs peak, demonstrating that the method is specific.

System suitability and system repeatability
The reproducibility aspects of any chromatographic system have been checked through system suitability and system repeatability parameters (Table 3).

Linearity
The method was found to be linear for BSL and AMD from 60% to 140% of the nominal working concentration in the range of 60.08–140.19 µg/ml and 59.73–139.37 µg/ml with squared correlation coefficient \( R^2 \) of 0.999 in both cases. Linearity results proved an excellent linear relationship for BSL and AMD in the studied concentration range, signifying the method suitability for analysis. Linearity study results are summarized in Table 4 and plots are shown in Figure 7.

Detection limit and quantitation limit
The DL was 2.29 µg/ml for BSL and 2.23 µg/ml for AMD, respectively, indicating that even small quantities of BSL and AMD can be detected.

The QL was 6.94 µg/ml for BSL and 6.74 µg/ml AMD, respectively, indicating that even small quantities of BSL and AMD can be quantified.

Accuracy
The results of mean percent recovery obtained from triplicate samples at all level were found to be 99.26%, 99.81%, and 98.97% for BSL and 98.70%, 99.61%, and 99.26% for AMD at 60%, 100%, and 140% of nominal working concentration, respectively, indicating that the method is accurate and shows that the excipients have no interference in the estimation (Table 5).

Precision
The results of method repeatability and intermediate precision showed that the % RSD values were less than 2.0 for

| Parameters                  | Description                                      |
|-----------------------------|--------------------------------------------------|
| Type of system              | HPLC with UV detector or equivalent               |
| Mobile phase (Eluent)       | 20 mM phosphate buffer pH 2.5: Methanol: Acetonitrile (420:290:290, v/v/v) |
| Column                      | Oyster ODS3 (150 × 4.6 mm, 5 µm) column (P/N: S670153, Make: Merck & Co.) |
| Detection wavelength        | 230 nm                                           |
| Flow rate                   | 1.0 ml/minute                                    |
| Volume of injection         | 20 µl                                            |
| Temperature of column       | Ambient (about 25°C)                             |
| Pump mode                   | Isocratic                                        |
| Run time                    | 10 minutes                                       |
| Diluent/solvent             | Mobile phase used as diluent                     |

Figure 8. Results of greenness AGREE analysis for HPLC method. (a) Current method; (b) Patil et al.’s (2017) method; (c) Patil et al.’s (2014) method; (d) Pant and Pal’s (2012) method; (e) Baokar et al.’s (2011) method; and (f) Vora and Kadav’s (2008) method.
Table 2. Summarized results of forced degradation study.

| Name of the sample | Condition | Drug substance | | % assay | % total degradation | % mass balance | | Drug product | | % assay | % total degradation | % mass balance |
|-------------------|-----------|----------------|--------|----------|-------------------|---------------|--------|----------------|----------------|----------------|----------------|
|                   |           | BSL            | AMD    | BSL      | AMD              | BSL           | AMD    | BSL            | AMD            | BSL            | AMD            |
| Unstressed        | As per test method | 99.88 | 98.99 | NTD | NTD | 99.88 | 98.99 | 98.76 | 99.66 | NTD | NTD | 98.76 | 99.66 |
| Acid-stressed     | 5 N HCl for 3 hours at RT | 96.08 | 97.06 | 1.65 | 0.96 | 97.73 | 98.02 | 96.02 | 97.07 | 2.09 | 1.78 | 98.11 | 98.85 |
| Alkali stressed   | 5 N NaOH for 3 hours at RT | 99.16 | 95.58 | NTD | 2.78 | 99.16 | 98.36 | 98.92 | 93.44 | 3.52 | 2.92 | 98.92 | 96.96 |
| Oxidative stressed| 6% H₂O₂ for 3 hours at RT | 99.44 | 99.53 | NTD | NTD | 99.44 | 99.53 | 100.25 | 98.79 | NTD | NTD | 100.25 | 98.79 |
| Thermal stressed  | 60°C for 48 hours in Oven | 99.50 | 100.16 | NTD | NTD | 99.50 | 100.16 | 97.86 | 91.15 | 5.83 | 5.83 | 97.86 | 98.53 |
| Photolytic-stressed| UV light for 24 hours | 98.10 | 99.50 | NTD | 0.52 | 98.10 | 100.02 | 97.63 | 96.79 | NTD | NTD | 97.63 | 96.79 |
| Humidity stressed | 75% RH for 48 hours | 100.10 | 99.47 | NTD | NTD | 100.10 | 99.47 | 99.40 | 98.00 | NTD | NTD | 99.40 | 98.00 |

NTD = Not detected; RT = Room temperature; RH = Relative humidity.

Table 3. System suitability and system repeatability results.

| Parameters | BSL | AMD | Acceptance criteria |
|------------|-----|-----|---------------------|
| Retention time (minutes) | 2.543 | 4.883 | – |
| USP tailing factor (symmetry factor) | 1.45 | 1.23 | 0.8–2.0 |
| USP plate counts (number of theoretical plates) | 4,526 | 3,631 | >2,000 |
| USP resolution | – | 9.79 | >5.0 |
| % RSD of five replicate injections of standard 1 | 0.45 | 0.33 | ≤2.0% |
| The % relative difference between two standards | 1.31 | 1.14 | ≤2.0% |

Table 4. Summarized linearity study results.

| Linearity level (%) | Concentration (µg/ml) | Peak area response |
|---------------------|-----------------------|--------------------|
|                     | BSL | AMD | BSL | AMD |
| 60                  | 60.08 | 59.85 | 79,924 | 158,760 |
| 80                  | 80.11 | 79.80 | 106,391 | 211,575 |
| 100                 | 100.14 | 99.75 | 134,291 | 266,669 |
| 120                 | 120.17 | 119.70 | 158,107 | 316,024 |
| 140                 | 140.19 | 139.65 | 185,063 | 374,126 |
| % RSD from zero (r²); ≥0.995 | 0.999 | 0.999 |

Squared correlation coefficient ($r^2$); ≥0.995 0.999 0.999

(Y-intercept/response at 100% standard concentration) * 100; ≤3.0%

Table 5. Summarized results for accuracy study.

| Accuracy level (%) | Concentration (µg/ml) | Mean % recovery* | % RSD |
|-------------------|-----------------------|------------------|-------|
|                   | BSL | AMD | BSL | AMD | BSL | AMD | BSL | AMD |
| 60                | 60 | 60 | 99.26 | 98.70 | 0.93 | 0.32 |
| 100               | 100 | 100 | 99.81 | 99.61 | 0.27 | 0.34 |
| 140               | 140 | 140 | 98.97 | 99.26 | 0.99 | 0.62 |

*Mean of three replicates.

Table 6. Summarized % assay results of precision study.

| Sample no. | Method repeatability | Intermediate precision |
|------------|----------------------|------------------------|
|            | BSL | AMD | BSL | AMD |
| 1          | 99.53 | 100.08 | 100.30 | 100.10 |
| 2          | 98.94 | 98.52 | 100.11 | 99.10 |
| 3          | 98.58 | 98.54 | 100.19 | 100.09 |
| 4          | 101.81 | 100.53 | 100.48 | 99.89 |
| 5          | 98.24 | 101.43 | 100.56 | 99.20 |
| 6          | 98.97 | 98.92 | 99.92 | 98.74 |
| Average    | 99.35 | 99.67 | 100.26 | 99.52 |
| % RSD      | 1.29 | 1.20 | 0.24 | 0.58 |
| % Relative difference | NA | NA | 0.91 | 0.15 |

95% CI 98.23–100.47 | 98.63–100.71 | 100.05–100.47 | 99.01–100.03

NA = Not applicable.
Table 7. Robustness results for filter compatibility.

| Filter                              | Sample no. | BSL % assay | % relative Difference | AMD % assay | % relative Difference |
|-------------------------------------|------------|-------------|-----------------------|-------------|-----------------------|
| Whatman filter (As per method)      | 1          | 101.81      | NA                    | 100.53      | NA                    |
|                                     | 2          | 98.24       | NA                    | 101.43      | NA                    |
|                                     | 3          | 98.97       | NA                    | 98.92       | NA                    |
| 0.45 µm Nylon syringe filter        | 1          | 99.76       | 2.04                  | 98.91       | 1.63                  |
|                                     | 2          | 99.25       | 1.02                  | 99.69       | 1.73                  |
|                                     | 3          | 98.32       | 0.66                  | 97.89       | 1.05                  |
| 0.45 µm PVDF syringe filter         | 1          | 100.48      | 1.32                  | 99.83       | 0.70                  |
|                                     | 2          | 99.48       | 1.25                  | 100.45      | 0.97                  |
|                                     | 3          | 99.60       | 0.63                  | 98.63       | 0.29                  |

NA = Not applicable.

Table 8. Results of robustness for change in sonication time.

| Sample sonication (minutes) | Sample no. | BSL % assay | Average | % relative Difference | AMD % assay | Average | % relative Difference |
|-----------------------------|------------|-------------|---------|-----------------------|-------------|---------|-----------------------|
| 25 (as per method)          | 1          | 99.53       | 99.02   | NA                    | 100.08      | 99.05   | NA                    |
|                             | 2          | 98.94       | 98.52   |                       |             |         |                       |
|                             | 3          | 98.58       | 98.54   |                       |             |         |                       |
| 20                          | 1          | 98.92       | 99.58   | 0.57                  | 99.30       | 99.27   | 0.22                  |
|                             | 2          | 100.36      |         |                       | 99.61       |         |                       |
|                             | 3          | 99.47       |         |                       | 98.89       |         |                       |
| 30                          | 1          | 100.09      | 99.28   | 0.26                  | 99.74       | 100.25  | 1.21                  |
|                             | 2          | 98.33       |         |                       | 102.22      |         |                       |
|                             | 3          | 99.42       |         |                       | 98.80       |         |                       |

NA = Not applicable; % RD = % relative difference.

Table 9. Robustness results for change in chromatographic parameters.

| Variation in chromatographic conditions | Retention time (minute) | Plate count | Tailing factor | % RSD | Reso. | Retention time from sample |
|-----------------------------------------|-------------------------|-------------|----------------|-------|-------|---------------------------|
| **BSL**                                 | **AMD**                 | **BSL**     | **AMD**        | **BSL** | **AMD** | **BSL** | **AMD** |
| As per method                           | 2.529                   | 5.002       | 3,638          | 3,131 | 1.49  | 1.33  | 0.64  | 0.66  | 9.42  | 2.514 | 5.008 |
| Flow rate – 0.1 ml/minute               | 2.785                   | 5.557       | 3,901          | 3,276 | 1.43  | 1.31  | 0.82  | 0.53  | 9.78  | 2.776 | 5.488 |
| Flow rate + 0.1 ml/minute               | 2.278                   | 4.543       | 3,727          | 3,437 | 1.42  | 1.25  | 0.40  | 0.32  | 9.87  | 2.277 | 4.519 |
| Buffer phase – 10%                      | 2.316                   | 4.043       | 3,835          | 3,121 | 1.47  | 1.33  | 0.45  | 1.32  | 7.87  | 2.309 | 4.041 |
| Buffer phase + 10%                      | 2.673                   | 5.671       | 3,660          | 3,130 | 1.44  | 1.30  | 0.48  | 0.82  | 10.30 | 2.671 | 5.730 |
| pH of buffer – 0.2                      | 2.529                   | 4.959       | 3,789          | 3,498 | 1.42  | 1.28  | 0.29  | 0.41  | 9.73  | 2.496 | 4.845 |
| pH of buffer + 0.2                      | 2.520                   | 4.994       | 3,486          | 3,130 | 1.46  | 1.28  | 0.57  | 0.69  | 9.37  | 2.513 | 4.944 |
| Quantity of PDP – 10%                   | 2.446                   | 4.791       | 3,751          | 3,206 | 1.50  | 1.33  | 0.51  | 0.47  | 9.31  | 2.462 | 4.814 |
| Quantity of PDP + 10%                   | 2.563                   | 5.225       | 3,653          | 3,572 | 1.42  | 1.24  | 0.91  | 0.63  | 10.25 | 2.564 | 5.258 |
| Acceptance criteria                     | –                       | –           | >2000          |       |       | 0.8–2.0 | >2.0  |       |       | Similar to standard |

Reso. = USP resolution between BSL and AMD peak.
### Table 10. Standard solution stability (room temperature).

| Time in days | First standard solution | Second standard solution |  |
|--------------|-------------------------|--------------------------|---|
|              | Response/mg | % relative difference | Response/mg | % relative difference |  |
|              | Fresh standard | Stored standard |  | Fresh standard | Stored standard |  |
| BSL          |  |  |  |  |  |
| Initial      | 12,597.53 | NA | 12,764.90 | NA | NA |  |
| 1            | 12,546.92 | 12,456.24 | 0.73 | 12,546.92 | 12,747.00 | 1.57 |  |
| 2            | 12,554.83 | 12,403.07 | 1.22 | 12,554.83 | 12,678.40 | 0.97 |  |
| AMD          |  |  |  |  |  |
| Initial      | 18,268.87 | NA | 18,479.36 | NA | NA |  |
| 1            | 17,883.39 | 17,643.31 | 1.36 | 17,883.39 | 17,918.07 | 0.19 |  |
| 2            | 17,958.04 | 18,136.77 | 0.99 | 17,958.04 | 17,809.43 | 0.83 |  |

### Table 11. Standard solution stability (refrigerator, 2°C–8°C).

| Time in days | First standard solution | Second standard solution |  |
|--------------|-------------------------|--------------------------|---|
|              | Response/mg | % relative difference | Response/mg | % relative difference |  |
|              | Fresh standard | Stored standard |  | Fresh standard | Stored standard |  |
| BSL          |  |  |  |  |  |
| Initial      | 12,597.53 | NA | 12,764.90 | NA | NA |  |
| 1            | 12,546.92 | 12,666.53 | 0.94 | 12,546.92 | 12,617.70 | 0.56 |  |
| 2            | 12,554.83 | 12,536.73 | 0.14 | 12,554.83 | 12,592.30 | 0.30 |  |
| AMD          |  |  |  |  |  |
| Initial      | 18,268.87 | NA | 18,479.36 | NA | NA |  |
| 1            | 17,883.39 | 17,788.94 | 0.53 | 17,883.39 | 18,105.21 | 1.23 |  |
| 2            | 17,958.04 | 17,720.42 | 1.34 | 17,958.04 | 17,830.43 | 0.72 |  |

### Table 12. Summary of the results of stability of sample solutions.

| Time in day | Sample | Room temperature | Refrigerator (2°C–8°C) |  |
|-------------|--------|------------------|------------------------|---|
|              |        | % assay | % relative difference | % assay | % relative difference | % assay | % relative difference |  |
|              |        | BSL    | AMD | BSL | AMD | BSL    | AMD | BSL | AMD |  |
| Initial      | 1      | 99.53  | 100.08 | NA | NA | 99.53  | 100.08 | NA | NA |  |
| 2            | 98.94  | 98.52  | NA | NA | 98.94  | 98.52  | NA | NA |  |
| 3            | 98.58  | 98.54  | NA | NA | 98.58  | 98.54  | NA | NA |  |
| Day 1        | 1      | 99.78  | 99.82 | 0.25 | 0.26 | 98.07  | 100.95 | 1.48 | 0.86 |  |
| 2            | 98.74  | 100.02 | 0.20 | 1.52 | 99.54  | 98.12  | 0.60 | 0.41 |  |
| 3            | 99.80  | 98.76  | 1.23 | 0.22 | 100.75 | 99.87  | 2.18 | 1.34 |  |
| Day 2        | 1      | 99.63  | 99.00 | 0.10 | 1.09 | 99.80  | 99.59  | 0.27 | 0.49 |  |
| 2            | 98.80  | 97.98  | 0.14 | 0.55 | 100.27 | 99.42  | 1.33 | 0.91 |  |
| 3            | 98.32  | 100.56 | 0.27 | 2.03 | 98.91  | 99.26  | 0.34 | 0.72 |  |

NA = not applicable.
Table 13. Mobile phase stability results.

| Time in days | Retention time (minute) | Plate count | Tailing factor | % RSD | Reso. | RT from sample |
|--------------|-------------------------|-------------|---------------|-------|-------|----------------|
| BSL          | AMD                     | BSL         | AMD           | BSL   | AMD   | BSL            | AMD            |
| Initial      | 2.543                   | 4.883       | 4526          | 1.45  | 1.23  | 0.45           | 0.33           | 9.79           | 2.516          | 4.812          |
| 1            | 2.524                   | 4.961       | 4640          | 1.50  | 1.29  | 0.62           | 0.70           | 10.43          | 2.525          | 4.975          |
| 2            | 2.539                   | 4.979       | 4757          | 1.46  | 1.28  | 0.78           | 0.36           | 10.27          | 2.488          | 4.835          |

Acceptance criteria

- Reso. = Resolution between BSL and AMD peak
- RT = Retention time in minutes

Reso. = Resolution between BSL and AMD peak; RT = Retention time in minutes.

Table 14. Comparison of the reported methods for simultaneous estimation of BSL and AMD.

| Parameters                              | Vora and Kadav, 2008 | Baokar et al., 2011 | Pant and Pal, 2012 | Patil et al., 2014 | Patil et al., 2017 | Proposed method                        |
|-----------------------------------------|-----------------------|---------------------|--------------------|--------------------|--------------------|----------------------------------------|
| Type of system                          | HPLC with PDA detector| HPLC with UV detector| HPLC with PDA/UV detector| HPLC with UV detector| HPLC with UV detector| HPLC with UV detector                  |
| Mobile phase (Eluent)                   | 25 mM ammonium acetate adjusted to pH 5.0 with acetic acid and methanol (65:35, v/v) | Methanol:Acetonitrile:50 mM PDP buffer (25:30:45, v/v) at pH 3.0 | A mixture of buffer prepared by 0.4 ml of TEA and 3.12 g of sodium dihydrogen orthophosphate in 1,000 ml water adjusted to pH 3.0 ± 0.05 and acetonitrile (50:50, v/v) | Methanol, Acetonitrile, and 50 mM PDP buffer of pH 3.0 (25:30:45, v/v/v) | Acetonitrile:Methanol:20 mM PDP buffer pH 2.5:Methanol:Acetonitrile (420:290:290, v/v/v) |
| Column                                  | Luna C18-2 (50 × 4.6 mm ID, 3 μ) | C18 Intersil 4.6 × 150 mm (id)* | Luna C18 (250 × 4.6 mm, 5 μ), as well as Hibar (R) RP-18e (250 × 4.6 mm, 5 μ) | Kya Tech., Sil C-18 HS (250 × 4.6 mm, 10 μm) | Agilent C18 (250 × 4.6 mm, 5 μm) | Oyster ODS3 (150 × 4.6 mm, 5 μm) column (P/N: S670153, Make: Merck & Co.) |
| Detection wavelength                    | 230 nm                | 267 nm              | 230 nm             | 267 nm             | 274 nm             | 230 nm                                |
| Flow rate                               | 0.8 ml/ minute        | 1.0 ml/ minute      | 1.0 ml/ minute     | 1.0 ml/ minute     | 1.0 ml/ minute     | 1.0 ml/ minute                        |
| Temperature of column                   | Not reported          | Not reported        | 25°C               | Not reported       | Not reported       | Ambient (about 25°C)                  |
| Pump mode                               | Isocratic             | Isocratic           | Isocratic          | Isocratic          | Isocratic          | Isocratic                            |
| Run time                                | 5 minutes             | 12 minutes          | 10 minutes         | 10 minutes         | 15 minutes         | 10 minutes                           |
| Resolution between BSL and AMD peak    | 14.2                  | Not reported        | 7.46               | 14.08              | 4.42               | 9.79                                  |
| Greenness assessment using AGREE value  | 0.60                  | 0.59                | 0.54               | 0.57               | 0.56               | 0.60                                  |

Continued
Parameters | Vora and Kadav, 2008 | Baokar et al., 2011 | Pant and Pal, 2012 | Patil et al., 2014 | Patil et al., 2017 | Proposed method
--- | --- | --- | --- | --- | --- | ---
**Advantage** | 1. Short run time | Analysis time is 12 minutes | Analysis time is 10 minutes | 1. Analysis time is 10 minutes | 1. Analysis time is 10 minutes | 1. Analysis time is 10 minutes
2. Considered as Stability indicating method | | | | 2. Standard solution stability established | 2. Easy sample preparation (single step) | 3. Considered as stability indicating method
**Disadvantage** | FD performed only on DP not on DS as well as for humidity stressed condition | FD not performed | FD not performed | FD not performed | 1. Low resolution | Separation and structural characterization of degradants were not carried out
2. Long run time | 3. FD performed on DS as well as on DP but not performed for photolytic- and humidity-stressed condition | | | 1. Simultaneous determination of BSL and AMD in Tablets | 1. Simultaneous determination of BSL and AMD in Tablets
**Applications** | Simultaneous determination of BSL and AMD in tablets | Simultaneous determination of BSL and AMD | 1. Simultaneous determination of BSL and AMD in tablets | Simultaneous determination of BSL and AMD in tablets | Simultaneous determination of BSL and AMD in tablets | 1. Simultaneous determination of BSL and AMD in tablets
2. Dissolution | 2. Dissolution | | | | | 2. Stability sample analysis

*Particle size not reported by Author; FD = Forced degradation; DS = Drug substance; DP = Drug product.

BSL and AMD, demonstrating that the method is reproducible and precise (Table 6).

**Robustness**

The results of the sample filtered through 0.45 μm nylon syringe filter and 0.45 μm PVDF syringe filter met the acceptance criteria for % relative difference (it should be ≤3.0%) with results of sample filtered through Whatman filter paper (as per method). Thus, besides Whatman filter paper, 0.45 μm PVDF syringe filter and 0.45 μm nylon syringe filter were useful for assay samples (Table 7).

The results of extraction efficiency of BSL and AMD tablets 5/5 mg (CORBIS® AM – 5) were not influenced by altering the sample sonication time from 20 to 30 minutes, and as a result (Table 8) they met acceptance criteria for % relative difference (it should be ≤3.0%).

For each changed method parameter during robustness study, the results of system suitability, system repeatability, and change in retention time were checked. The acceptance criteria were met for each chromatographic method parameter even after making the deliberate changes into it, demonstrating its robustness (Table 9).

**Solution stability**

The results of standard solution stability at bench top (room temperature) and in the refrigerator (2°C–8°C) met the acceptance criteria (% relative difference between studied and initial time point is ≤2.0%), revealing that the standard solutions were stable for 2 days (Tables 10 and 11).
The sample solutions at bench top (room temperature) and in the refrigerator (2°C–8°C) were stable for 2 days as the % relative difference between the percent assay results (Table 12) obtained from initial sample solutions and stored sample solutions met the acceptance criteria (the % relative difference among initial and stored time point is ≤3.0%).

During estimation of mobile phase stability, the appearance of mobile phase was found to be clear and free of visible particles. Also, the system suitability and system repeatability results (Table 13) met the acceptance criteria, indicating that the mobile phase at bench top (room temperature) was stable for 2 days.

Based on solution stability data, it is recommended that standard solution, sample solution, and mobile phase can be used up to 2 days from their time of preparation.

**Range**

The method range is from 60% to 140% of the nominal working standard solution has been derived for BSL and AMD based on acceptable linearity, accuracy, and precision study results.

**Comparison of the reported methods for simultaneous estimation of BSL and AMD**

In comparison with the earlier reported work as well as conducting in-depth study in the current research, it was found that the current research offers various advantages like improved resolution, short run time, less time-consuming process, and also more eco-friendly (Table 14).

The results for system suitability and system repeatability parameters were established with preparations of two standard solutions. Moreover, robustness study provides additional benefits for filter compatibility study and change in sonication time. The solution stability was reported for preparations of mobile phase as well as for standard and sample solutions. The forced degradation study was also performed on drug substances individually and their combination drug product with a suitable experimental design. In addition to this, it is more economic as simple solution preparations require less time of analysis. The experimental results obtained during the validation recommend that this method is more simple, rapid, specific, precise, accurate, linear, and robust enough as compared to the reported methods.

A number of new tools for assessing the greenness of analytical procedures have recently been introduced, which includes National Environmental Methods Index, Eco-Scale Assessment, Green Analytical Procedure Index, and AGREE: Analytical GReeEnEss metric, and each metric system is characterized by their advantages and disadvantages (Gamal et. al., 2021). Green analytical chemistry aims to make analytical techniques less harmful to the environment and safer to human. The AGREE tool useful to convert each of the 12 green analytical chemistry criteria into scores with the goal of comprehensively evaluating the greenness of analytical methodologies (Pena-Pereira et. al., 2020). The current method of greenness was determined by using the software tool AGREE: Analytical GReeEnEss Calculator version 0.5 and was compared with the old HPLC methods (Fig. 8).

However, in the current work, the separation and structural characterization of degradants were not carried out. The current research can be extended further to separate out the degradants and structural characterization of the same to identify the correct chemical structures of drug degradation products which will help in providing better quality control and quality assurance attributes for pharmaceutical industries.

**CONCLUSION**

The RP-HPLC method with a stability-indicating feature for simultaneous determination of BSL and AMD in bulk and in tablet dosage form was developed and validated as per the guidelines of ICH. The study results show that the chromatographic method is linear in the measured concentration range as well as specific, accurate, precise, and robust. Experimental results of forced degradation study reveals that all the degradation peaks were well separated from the active component(s) peak, signifying the method is specific and stability-indicating. The percent recovery results for dosage forms indicated that there was no interference from the excipients in the active components determination. The values for % RSD were less than 2.0 for method repeatability and intermediate precision signifying the high level of method precision. The values for detection limits and quantitation limits provide additional benefits as it is found to be very low. The results of deliberate changes made in method parameters signify robustness of method. The results of solution stability reveal that the solutions of standard, sample, and mobile phase are stable for 2 days. In addition to this, drugs analysis is rapid and cost-effective as the method has easy extraction and sample preparation process with simple isocratic elution. The developed method can be useful for regular analysis as well as stability studies of BSL and AMD in the quality control of finished product and also in bulk manufacturing.

**CONFLICT OF INTEREST**

The authors declare no conflicts of interest.

**FUNDING**

None.

**AUTHOR CONTRIBUTIONS**

Each author contributed to the conception, design, and execution of this study and also agreed to submit to the current journal.

**ACKNOWLEDGMENT**

The authors would like to thanks RUSA Centre for Herbo Medicinal Studies and School of Pharmacy, Swami Ramanand Teerth Marathwada University, Nanded – 431606, Maharashtra – India for providing instrumental, laboratory, chemical and other required facilities during research work. Also, authors are thankful to Unichem Laboratories Ltd., Goa – India for supplying gift samples of Bisoprolol Fumarate and Amlodipine Besylate.
REFERENCES

Alsante KM, Baertschi SW, Coutant M, Marquez BL, Sharp TR, Zelesky TC. Degradation and impurity analysis for pharmaceutical drug candidates. In: Ahuja S, Scypinski S (eds.). Handbook of modern pharmaceutical analysis, Elsevier Science Publishing Co Inc., San Diego, CA, pp 59–169.

Aubry AF, Tattersall P, Ruan J. Development of stability indicating methods. In: Huynh-Ba K (ed.). Handbook of stability testing in pharmaceutical development, Springer, New York, NY, pp 139–61.

Baokar SB, Erande RS, Shaikh SG. Analytical method development and validation for simultaneous determination of bisoprolol fumarate and amlodipine besylate. Indo Am J Pharm Res, 2011; 2(1):100–10.

Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal, 2014; 4(3):159–65.

Da Silva Medeiros T, Pinto EC, Cabral LM, De Sousa VP. Tobramycin: a review of detectors used in analytical approaches for drug substance, its impurities and in pharmaceutical formulation. Microchem J, 2020; 160(B):105658.

European Pharmacopoeia 10.0. European directorate for the quality of medicines and healthcare, 2020.

Gamal M, Naguib IA, Panda DS, Abdallah FF. Comparative study of four greenness assessment tools for selection of greenuest analytical method for assay of hyoscine N-butyl bromide. Anal Methods, 2021; 13(3):369–80.

Gamal M. Analytical review: analytical techniques for hyoscyine N butyl bromide. Analyst, 2020; 145(6):2025–37.

Hosny NM. A review on: analysis of the first oral, direct factor Xa inhibitor; rivaroxaban. Microchem J, 2020; 159:105336.

Hostalek U, Koch EMW. Treatment of hypertension with a fixed-dose combination of bisoprolol and amlodipine in daily practice: results of a multinational non-investigational study. Cardiovasc Disord Med, 2016; 1(3):1–5.

ICH. ICH guideline Q1A (R2). Stability testing of new drug substances and products. In International Conference on Harmonization, Geneva, Switzerland, 2003.

ICH. ICH guideline Q2A (R1). Validation of analytical procedures: text and methodology. In International Conference on Harmonization, Geneva, Switzerland, 2005.

Indian Pharmacopoeia. Government of India, Ministry of Health and Family Welfare, Indian Pharmacopoeia Commission, Gaziabad, India,

Mohammed F, Guillaume D, Warland J, Abdulwali N. Analytical methods to detect adulteration of argan oil: a critical review. Microchem J, 2021; 168:106501.

Pant S, Pal K. Development and validation of a simultaneous HPLC method for assay and dissolution of bisoprolol fumarate and amlodipine besylate in pharmaceutical Dosage. Res J Pharm Dos Forms Technol, 2012; 4(1):62–6.

Patil V, Devdhe S, Kale S, Kawade S, Pati R. Development and validation of new RP-HPLC method for the estimation of amlodipine besylate and bisoprolol fumarate in bulk and tablet dosage form. J Indian Chem Soc, 2014; 91(3):373–9.

Patil VS, Talele AN, Narkhede SB. Development and validation of chromatographic and spectrophotometric method for simultaneous estimation of amlodipine besilate and bisoprophol fumarate in tablet dosage form. European J Biomed Pharm Sci, 2017; 4(4):502–14.

Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE—Analytical GREEmness metric approach and software. Anal Chem, 2020; 92(14):10076–82.

Thakur A, Mishra B, Mahata PP. Pharmaceutical impurities: a review. Int J Pharm Chem, 2015; 5:232–9.

United State Pharmacopeia. United State Pharmacopoeia USP 42–NF 37. US Pharmacopoeial Convention Inc., Washington, DC.

Vora D, Kadav A. Development and validation of a simultaneous HPLC method for estimation of bisoprolol fumarate and amlodipine besylate from tablets. Indian J Pharm Sci, 2008; 70(4):542–6.

How to cite this article:

Gholve RB, Pekamwar SS, Kalyankar TM. Stability-indicating RP-HPLC method development and validation for simultaneous estimation of bisoprolol fumarate and amlodipine besylate in bulk and in tablet dosage form. J Appl Pharm Sci, 2021; 11(12):121–134.